Home
ALMS
ALMS News

Latest ALUMIS INC (ALMS) News on July 14, 2025

Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy

Clinical Trials Arena

a month ago

Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy

Alumis to Present at the Jefferies Global Healthcare Investor Conference

GlobeNewswire

2 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Analysts' Revenue Estimates For Alumis Inc. (NASDAQ:ALMS) Are Surging Higher

Simply Wall St.

2 months ago

Analysts' Revenue Estimates For Alumis Inc. (NASDAQ:ALMS) Are Surging Higher

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

GlobeNewswire

2 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

MT Newswires

2 months ago

Alumis, Acelyrin Close Merger

Alumis Completes Merger with ACELYRIN

GlobeNewswire

2 months ago

Alumis Completes Merger with ACELYRIN

MT Newswires

2 months ago

Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

GlobeNewswire

2 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

MT Newswires

2 months ago

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires

2 months ago

Alumis, Acelyrin Shareholders Approve Merger Deal

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

GlobeNewswire

2 months ago

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

GlobeNewswire

2 months ago

Alumis Stockholders Approve Merger with ACELYRIN

MT Newswires

2 months ago

Alumis Insider Bought Shares Worth $1,477,312, According to a Recent SEC Filing

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

GlobeNewswire

2 months ago

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

Acelyrin urges stockholders to vote for proposed merger with Alumis

TipRanks

2 months ago

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

GlobeNewswire

2 months ago

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Acelyrin should liquidate instead of merging with Alumis, investor says

BioPharma Dive

3 months ago

Acelyrin should liquidate instead of merging with Alumis, investor says

MT Newswires

3 months ago

Alumis Raises Share Consideration for Acelyrin Acquisition

Alumis and ACELYRIN Announce Amended Merger Agreement

GlobeNewswire

3 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

Insider Buying: Alumis Independent Director Bought US$130k Of Shares

Simply Wall St.

3 months ago

Insider Buying: Alumis Independent Director Bought US$130k Of Shares

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

GlobeNewswire

3 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken sign agreement in Japan to develop ESK-001

Pharmaceutical Technology

4 months ago

Alumis and Kaken sign agreement in Japan to develop ESK-001

MT Newswires

4 months ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

MT Newswires

4 months ago

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

GlobeNewswire

4 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Why Alumis Inc. (ALMS) Went Down On Thursday?

Insider Monkey

4 months ago

Why Alumis Inc. (ALMS) Went Down On Thursday?

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

GlobeNewswire

4 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

GlobeNewswire

4 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

GlobeNewswire

4 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

MT Newswires

4 months ago

Acelyrin Reaffirms Merger Deal With Alumis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

GlobeNewswire

4 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

GlobeNewswire

4 months ago

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

GlobeNewswire

4 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

GlobeNewswire

5 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

GlobeNewswire

5 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

GlobeNewswire

5 months ago

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

5 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

MT Newswires

5 months ago

Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating

Alumis and Acelyrin sign merger agreement

Pharmaceutical Technology

5 months ago

Alumis and Acelyrin sign merger agreement

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Simply Wall St.

5 months ago

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Immune drugmakers Alumis and Acelyrin to merge

BioPharma Dive

5 months ago

Immune drugmakers Alumis and Acelyrin to merge

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

GlobeNewswire

5 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

GlobeNewswire

6 months ago

Alumis Strengthens Leadership Team with Key Appointments

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Simply Wall St.

7 months ago

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

GlobeNewswire

7 months ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

GlobeNewswire

8 months ago

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

GlobeNewswire

8 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

GlobeNewswire

8 months ago

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

GlobeNewswire

10 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis to Participate in Upcoming September Investor Conferences

GlobeNewswire

10 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

GlobeNewswire

a year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

GlobeNewswire

a year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Share on Social Networks: